Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q2 FY27 consolidated total income ₹3,770 Cr +32% y-y; PAT ₹1,127 Cr +64% y-y - First half FY27 total income ₹6,907 Cr +28% y-y; PAT ₹2,029 Cr +64% y-y - Exports ~90% of standalone sales; Europe & North America ~75% of sales - Custom synthesis 62% and generics 38% of sales in H1 FY27 - Capex ₹1,223 Cr in H1 FY27; CWIP ₹1,638 Cr as of Sep 30, 2026 - Supply chain stable despite geopolitical and logistics challenges; 3-month inventory coverage maintained - Peptide capacity expansion ongoing with multiple 3,000 litre SPPS lines; focus on integrated manufacturing - Three major dedicated CS projects near commercialization; ramp-up expected in next few quarters - FY27 capex guidance ~₹2,000 Cr ±20%; investments across all units and technologies - Double-digit revenue growth guidance for H2 FY27; EBITDA margin guidance unchanged - No current capacity shortage; capacity additions aligned with customer demand - Multiple analyst queries on validation batches and peptide capacity; management cautious on specifics due to confidentiality